Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Introduction In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimumab improved progression-free survival in patients w...

Descripció completa

Dades bibliogràfiques

Autors principals:	John Haanen, Marco Donia, Inge Marie Svane, Bastiaan Nuijen, Cynthia Nijenhuis, Valesca P Retèl, Tine Monberg, Renske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Melanie Lindenberg, Wim van Harten
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2024-03-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/12/3/e008372.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!